Jeffrey Poulton

Chief Financial Officer & Executive Vice President, Alnylam

Search every verified Jeffrey Poulton interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jeffrey Poulton, Chief Financial Officer and Executive Vice President at Alnylam Pharmaceuticals, participated in the company’s Q1 and Q2 2026 earnings calls. In the Q1 call, he discussed U.S. results, noting $59 million in growth that was primarily demand-driven, with some positive inventory impacts offset by pricing trends. He also addressed questions about selling weeks and demand growth for the product Ambutra, acknowledging that insurance reauthorizations were part of the quarter’s story. In the Q2 call, Poulton stated that the company’s original guidance was not accurate, saying, “Guiding the market’s expectations appropriately is important and we didn’t get it right with our original guidance. We own that.” He explained that revised guidance reflected a better understanding of second-line demand evolution as the launch progressed, while noting that the Ambutra cardiomyopathy launch continued to perform ahead of analogues, with particular satisfaction regarding first-line uptake. Poulton also commented on competitive dynamics, comparing Alnylam’s RNAi mechanism with an ASO approach used by another company, noting that both knock down TTR but differ in mechanism and knockdown duration. He discussed the addressable patient population for hereditary hemorrhagic telangiectasia, estimating about 70,000 patients in the United States, while noting that epidemiology would firm up as effective treatments become available.